Comparison of linezolid and daptomycin in the treatment of vancomycin-resistant enterococcal bacteremia

Infectious Diseases in Clinical Practice

Volumn 19, Issue 5, 2011, Pages 343-347

  Bio, Laura L ^a   Perez, Mirza E ^b   MacDougall, Conan ^c   Gallagher, Jason C ^b  

^a UNIVERSITY OF THE SCIENCES   (United States)

^b TEMPLE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

bacteremia; daptomycin; Enterococcus; linezolid; vancomycin

Indexed keywords

DAPTOMYCIN; LINEZOLID; VANCOMYCIN;

ABDOMINAL INFECTION; ADULT; AGED; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BLOOD CULTURE; CATHETER INFECTION; CATHETER REMOVAL; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; ENTEROCOCCAL INFECTION; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ENTEROCOCCUS GALLINARUM; ENTEROCOCCUS RAFFINOSIS; FEMALE; HOSPITAL ADMISSION; HUMAN; INDWELLING CATHETER; INTENSIVE CARE UNIT; INTRAVENOUS CATHETER; MAJOR CLINICAL STUDY; MALE; REINFECTION; RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

EID: 80052660972     PISSN: 10569103     EISSN: 15369943     Source Type: Journal    
DOI: 10.1097/IPC.0b013e31822b7f6e     Document Type: Article

References (20)

1. Deshpande LM, Fritsche TR, Moet GJ, et al. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North American and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis. 2007;58:163-170. (Pubitemid 46856806)
2. National Nosocomial Infections Surveillance (NNIS) System. Report: data summary from January 1992Y2001, issued August 2001. Am J Infect Control. 2001;29:404-421.
3. DiazGranados CA, Zimmer SM, Klein M, et al. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis. 2005;41:327-333. (Pubitemid 41022109)
4. Smith PF, Booker BM, Ogundele AB, et al. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against gram-positive bacterial isolates from a large cancer center. Diagn Microbiol Infect Dis. 2005;52:255-259. (Pubitemid 41133552)
5. Sader HS, Jones RN, Stilwell MG, et al. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn Microbiol Infect Dis. 2005;52:181-186. (Pubitemid 41133543)
6. Zyvox (linezolid) [package insert]. New York, NY: Pharmacia & Upjohn Company, Division of Pfizer Inc; July 2008.
7. Cubicin (daptomycin) [package insert]. Lexington, MA: Cubist Pharmaceuticals, Inc; August 2008.
8. Gallagher JC, Perez ME, Marino EA, et al. Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients. Pharmacotherapy. 2009;29:792-799.
9. Charlson M, Szatrowski TP, Peterson J, et al. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245-1251. (Pubitemid 24361532)
10. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818-829. (Pubitemid 15250137)
11. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Testing: 17th Informational Supplement. CLSI document M100-S17. Wayne, PA: NCCLS, 2007.
12. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health careYassociated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36:309-332. (Pubitemid 351763841)
13. Cockcroft D. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
14. Linden PK, Moellering RC Jr, Wood CA, et al. Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/ dalfopristin. Clin Infect Dis. 2001;33: 1816-1823. (Pubitemid 33105119)
15. Moellering RC, Linden PK, Reinhardt J, et al. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium: synercid emergency-use study group. J Antimicrob Chemother. 1999;44:251-261. (Pubitemid 29389289)
16. Birmingham MC, Rayner CR, Meagher AK, et al. Linezolid for the treatment of multi-drug resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis. 2003;36:159-168. (Pubitemid 36143412)
17. Linden PK. Optimizing therapy for vancomycin-resistant enterococci (VRE). Semin Respir Crit Care Med. 2007;28:632-645.
18. Mohr JF, Friedrich LV, Yankelev S, et al. Daptomycin for the treatment of enterococcal bacteremia: results from the Cubicin Outcomes Registry Experience (CORE). Int J Antimicrob Agents. 2009;33:543-548.
19. Mave V, Garcia-Diaz J, Islam T, et al. Vancomycin-resistant enterococcal bacteremia: is daptomycin as effective as linezolid? J Antimicrob Chemother. 2009;64:175-180.
20. Erlandson KM, Sun J, Iwen PC, et al. Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant enterococcus bacteremia. Clin Infect Dis. 2008;46:30-36. (Pubitemid 351263556)